Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Marvell raises FY27 revenue forecast to $11.5B, driven by AI custom silicon and optical interconnect growth.

Analyst Insights
28 Jun 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Marvell increased its fiscal year 2027 revenue guidance to about $11.5 billion, a 40% year-over-year growth, with further growth expected in FY28 to $16.5 billion. This optimistic outlook is supported by strong demand in AI infrastructure, particularly from custom silicon products like Trainium and Maia, and optical interconnect technologies. The company is positioned uniquely with dual growth engines in AI hardware, setting it apart from peers. Investors should watch for the Q2 FY27 results in late August as a key milestone, though volatility with 20-25% drawdowns is anticipated along the way.

More News (MRVL)

Marvell and Broadcom report strong AI-driven earnings but differ in margins and growth outlooks.

Marvell and Broadcom report strong AI-driven earnings but differ in margins and growth outlooks.

Marvell Technology and Broadcom both posted impressive AI-driven earnings beats, yet their business models differ significantly. Marvell's revenue grew 27.6% YoY with a focus on custom silicon for hyperscalers, but it has lower gross margins around 5...

Company Fundamentals
Bullish
1 day ago
New ETFs focus on AI and space tech firms like Meta, OpenAI, and SpaceX, signaling a shift from legacy tech giants.

New ETFs focus on AI and space tech firms like Meta, OpenAI, and SpaceX, signaling a shift from legacy tech giants.

The ETF market is seeing a new trend with multiple firms launching 'MANGOS' ETFs that include AI and commercial space technology companies such as Meta, Anthropic, Nvidia, Google, OpenAI, and SpaceX. This marks a shift from the traditional 'Magnifice...

Market News
Bullish
2 days ago
Marvel Biosciences highlights autism drug research at European Purine Meeting, advancing MB-204 to clinical trials.

Marvel Biosciences highlights autism drug research at European Purine Meeting, advancing MB-204 to clinical trials.

Marvel Biosciences announced that Dr. Jérôme Becker will present research on Adenosine A2A receptors as a therapeutic target for autism at the European Purine Meeting in France. The company's lead drug candidate, MB-204, an A2A receptor antagonist, h...

Others
Bullish
2 days ago
Micron shares drop nearly 5% despite record earnings amid AI spending concerns

Micron shares drop nearly 5% despite record earnings amid AI spending concerns

Micron Technology's stock fell nearly 5% in premarket trading after a strong earnings report that saw its revenue quadruple year-over-year to $41.46 billion. Despite this, investors are cautious due to rising costs associated with building AI infrast...

Market News
Bearish
2 days ago
Marvell Technology stock jumps 220% with strong data center growth and raised outlooks.

Marvell Technology stock jumps 220% with strong data center growth and raised outlooks.

Marvell Technology's stock has surged over 220% since last September, driven by strong growth in its data center business which now accounts for 76% of total revenue. The company expects its interconnect business to grow 70% in fiscal year 2027 and c...

Analyst Insights
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App